AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
ADMA Biologics Q2 Earnings Preview: Expecting $0.14 EPS and $121.77M Revenue
ByAinvest
Tuesday, Aug 5, 2025 5:41 pm ET1min read
ADMA Biologics is set to release Q2 2025 earnings on August 6th, with a consensus EPS estimate of $0.14 and revenue estimate of $121.77M (+13.6% Y/Y). Over the last 3 months, EPS estimates have seen a decline, while revenue estimates have remained relatively stable.
ADMA Biologics, Inc. (ADMA) is scheduled to release its second-quarter 2025 earnings on August 6th, with analysts expecting earnings of $0.14 per share and revenue of $121.77 million. The consensus estimate reflects a year-over-year growth rate of 13.6% in revenue, while earnings per share (EPS) estimates have seen a decline over the past three months.In its previous quarterly report, ADMA Biologics reported a 40.2% increase in revenue year-over-year but missed earnings expectations, reporting $0.14 EPS against an anticipated $0.16. The company's revenue for the quarter was $114.80 million, compared to the consensus estimate of $116.40 million. The company's net margin was 45.01%, and its return on equity was 47.16%.
Over the past 90 days, revenue estimates for ADMA Biologics have remained relatively stable, with the full year 2025 revenue estimate at $0.51 billion. Conversely, earnings estimates have declined from $0.71 per share to $0.61 per share for the full year 2025 [1].
ADMA Biologics operates as an end-to-end commercial biopharmaceutical company, manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients and others at risk for infectious diseases. The company's products include ASCENIV™, BIVIGAM®, and NABI-HB®, with SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, in development.
The company's management team will host a live conference call and audio webcast on August 6th at 4:30 p.m. ET to discuss its financial results and other updates. Investors are encouraged to register for the call to receive the dial-in numbers and unique PIN [2].
References:
[1] https://www.gurufocus.com/news/3035133/adma-biologics-inc-adma-q2-2025-earnings-report-preview-what-to-look-for
[2] https://www.biospace.com/press-releases/adma-biologics-to-report-second-quarter-2025-financial-results-on-august-6-2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet